AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline
Pharmaceutical Investing Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
